Inquiry Basket
RNA interference (RNAi) has revolutionized gene therapy, with small interfering RNA (siRNA) being a key player in silencing disease-causing genes. However, challenges in efficient delivery and off-target effects have limited its full therapeutic application. siRNA conjugates represent a sophisticated strategy to enhance the stability, delivery, and specificity of siRNA-based therapeutics. At BOC Sciences, we specialize in the design and development of diverse siRNA conjugate delivery systems, offering tailored solutions that improve the pharmacokinetics, target specificity, and overall effectiveness of siRNA therapies.
siRNA conjugates involve the chemical attachment of siRNA molecules to various functional groups, carriers, or ligands to improve their cellular uptake, stability, and therapeutic potential. These conjugates offer several advantages, including targeted delivery to specific tissues or cells, enhanced resistance to enzymatic degradation, and reduced off-target effects. The core strategy behind siRNA conjugation is to overcome the barriers of free siRNA, such as poor cellular uptake, rapid clearance, and undesired immune responses, thus ensuring more efficient gene silencing. BOC Sciences has developed a range of siRNA conjugates, each tailored to specific therapeutic needs.
At BOC Sciences, we offer advanced siRNA conjugate delivery systems designed to enhance the therapeutic efficacy and precision of RNA interference (RNAi) treatments. Below are key delivery systems that we specialize in:
| siRNA Conjugates Delivery Systems | Description | Get a Quote |
| Dynamic Polyconjugates (DPC) | Dynamic Polyconjugates (DPC) are one of the most innovative siRNA delivery platforms, utilizing dynamic changes in polymer properties to facilitate targeted siRNA delivery. These conjugates are engineered to remain stable during circulation but degrade upon reaching the target cell, allowing the siRNA to be released intracellularly. By modifying the backbone chemistry and incorporating cleavable linkers, DPCs enhance cellular uptake and reduce off-target effects. | Inquiry |
| Cholesterol-siRNA Conjugates | Cholesterol-siRNA conjugates leverage the natural affinity of cholesterol for cellular membranes to enhance siRNA delivery. Cholesterol conjugation increases the hydrophobicity of siRNA, facilitating its integration into lipid bilayers and improving uptake by cells. This method has been widely used in liver-targeted therapies due to the natural liver tropism of cholesterol. The non-toxic nature and biodegradability of cholesterol make it an attractive candidate for siRNA conjugation. | Inquiry |
| Antibody-siRNA Conjugates | Antibody-siRNA conjugates combine the specificity of antibodies with the gene-silencing ability of siRNA, creating a targeted approach for delivering siRNA to specific cell types or tissues. By conjugating siRNA to monoclonal antibodies that recognize specific surface markers on diseased cells, this approach minimizes off-target gene silencing and enhances therapeutic efficacy. This conjugate system has been particularly useful in oncology, where siRNA can be delivered directly to cancer cells. | Inquiry |
| Nanoparticle-siRNA Conjugates | Nanoparticles offer a versatile platform for siRNA delivery. Nanoparticle-siRNA conjugates are engineered to encapsulate or attach siRNA molecules to a nanoparticle core, which can be functionalized with targeting ligands for specific tissue delivery. Nanoparticles protect siRNA from degradation in the bloodstream and facilitate endosomal escape once inside the target cells. | Inquiry |
| Peptide-siRNA Conjugates | Peptide-based conjugates are another promising platform for siRNA delivery. Peptide-siRNA conjugates use cell-penetrating peptides (CPPs) to enhance cellular uptake. CPPs can traverse cellular membranes, delivering attached siRNA directly into the cytoplasm, where gene silencing occurs. | Inquiry |
| Polymer-siRNA Conjugates | Polymer-siRNA conjugates involve attaching siRNA to biocompatible polymers such as polyethylene glycol (PEG) or poly(lactic-co-glycolic acid) (PLGA). These polymers not only protect siRNA from enzymatic degradation but also improve circulation time in the bloodstream. PEG-siRNA conjugates, for instance, have been shown to reduce immune responses while maintaining efficient gene silencing. | Inquiry |
| GalNAc-siRNA Conjugates | The GalNAc-siRNA conjugate system is particularly advantageous for targeting liver cells. Galactosamine (GalNAc) receptors are highly expressed on hepatocytes, making this a natural method for liver-specific siRNA delivery. This conjugation strategy enhances the selective uptake of siRNA by liver cells, significantly improving the therapeutic index. | Inquiry |
| Aptamer-siRNA Conjugates | Aptamers are short, single-stranded oligonucleotides that can bind to specific molecular targets with high affinity. Aptamer-siRNA conjugates exploit this property for targeted delivery, allowing siRNA to reach specific tissues or cells. This platform offers high specificity, reducing the likelihood of off-target effects and immune activation. | Inquiry |
| Folic acid–siRNA Conjugates | Folic acid-siRNA conjugates utilize folate receptors, which are overexpressed in many cancer cells, to deliver siRNA selectively to tumor tissues. This strategy enhances the therapeutic window by concentrating the siRNA within the tumor environment, thereby minimizing systemic exposure and off-target gene silencing. | Inquiry |
| CpG-siRNA Conjugates | CpG-siRNA conjugates combine siRNA with CpG oligodeoxynucleotides, which can activate the immune system by engaging toll-like receptor 9 (TLR9). This dual approach offers not only gene silencing but also an immune-stimulating effect, making it ideal for applications in cancer immunotherapy. | Inquiry |
| Nanobody siRNA Conjugates | Nanobody-siRNA conjugates offer a highly specific and efficient platform for delivering siRNA to target cells. Nanobodies, derived from camelid antibodies, are smaller and more stable than conventional antibodies, enabling better tissue penetration and reduced immunogenicity. By attaching siRNA to nanobodies, BOC Sciences provides an innovative approach to siRNA delivery, particularly useful in cancer and autoimmune diseases. | Inquiry |
| Centyrin siRNA Conjugates | Centyrin-siRNA conjugates utilize centyrins, which are small, engineered protein binders. Like nanobodies, centyrins offer a highly specific targeting mechanism but with improved stability and lower production costs. BOC Sciences has developed centyrin-siRNA conjugates to address difficult-to-target cells, opening new avenues for therapeutic applications. | Inquiry |
| Lipid siRNA Conjugates | Lipid siRNA conjugation, such as C16-siRNA, improves membrane permeability and systemic delivery. This approach is particularly useful for delivering siRNA to tissues with high lipid content, such as the liver. BOC Sciences offers lipid-conjugated siRNA designed to optimize delivery efficiency while minimizing off-target effects. | Inquiry |
At BOC Sciences, we offer an advanced siRNA conjugates service that stands out due to its combination of precision, innovation, and tailored solutions. Our expertise in this area allows us to provide clients with cutting-edge siRNA conjugate technology optimized for specific therapeutic needs.
Our team designs and synthesizes custom siRNA conjugates to meet the specific needs of each client. Whether it's targeting liver cells with GalNAc-siRNA conjugates or delivering siRNA to tumor cells with antibody-siRNA conjugates, we provide highly customized solutions based on your therapeutic targets. Our expertise ensures that the conjugates are optimized for the best biological response and efficacy.
siRNA molecules are susceptible to degradation in the bloodstream. By employing various conjugation strategies, such as attaching lipids, polymers, or peptides, we enhance the stability of siRNA, preventing rapid enzymatic degradation and increasing circulation time. This ensures that more siRNA reaches the target tissue or cells, thereby improving therapeutic outcomes.
Targeted delivery is one of the most critical factors for successful siRNA therapies. BOC Sciences excels at developing siRNA conjugates that improve tissue or cell-specific delivery, reducing off-target effects. Conjugates such as aptamer-siRNA or folic acid-siRNA direct the siRNA to particular tissues or tumor cells, ensuring more efficient gene silencing where it's needed most.
From the initial concept through to the final product, BOC Sciences offers a comprehensive, end-to-end service for the design, synthesis, and testing of siRNA conjugates. This full-service approach ensures that clients receive a well-rounded solution, including synthesis optimization, delivery strategies, and in vivo testing support.
Global Supplier of High-Quality RNA / DNA Products & Services.
